Comparison of thoracic radiotherapy efficacy between patients with and without EGFR-mutated lung adenocarcinoma

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

To investigate the association between tumor response to thoracic radiotherapy and epidermal growth factor receptor (EGFR) mutation status in patients with lung adenocarcinoma, we collected 48 patients treated between January 2010 and December 2013. Of the 18 patients with EGFR mutation, 15 (83.3%) had a single mutation, and three (16.7%) had double mutation. Different EGFR mutation subtypes exhibited different responses to radiotherapy. The identified double EGFR mutations were associated with reduction of residual tumor burden (RTB) after radiotherapy. In univariate analysis, EGFR mutations in exon 18, 20, and 21 and double EGFR mutation were significant factors predicting RTB. In multivariate analysis, exon 20 mutation was the only significant factor. Patients with EGFR mutation seemed to have longer mean overall survival (OS) compared to the group with wild-type EGFR (31.1 vs. 26.6 months, p=0.49). The median and mean OS in patients with double EGFR mutation vs. wild-type EGFR were 20.1 vs. 16.9 months and 28.9 vs. 26.6 months, respectively. Further studies with larger sample size are warranted to clarify the association of EGFR mutation status with the lung tumor response after radiotherapy.

Original languageEnglish
Pages (from-to)203-209
Number of pages7
JournalIn Vivo
Volume32
Issue number1
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Radiotherapy
Epidermal Growth Factor Receptor
Thorax
Mutation
Tumors
Residual Neoplasm
Tumor Burden
Exons
Adenocarcinoma of lung
Association reactions
Survival
Sample Size
Neoplasms
Multivariate Analysis

Keywords

  • Double EGFR mutation
  • Epidermal growth factor receptor mutation
  • Lung adenocarcinoma
  • Radiotherapy

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology

Cite this

@article{bf5d53f3c5df4f0c8d5f253ce91c0551,
title = "Comparison of thoracic radiotherapy efficacy between patients with and without EGFR-mutated lung adenocarcinoma",
abstract = "To investigate the association between tumor response to thoracic radiotherapy and epidermal growth factor receptor (EGFR) mutation status in patients with lung adenocarcinoma, we collected 48 patients treated between January 2010 and December 2013. Of the 18 patients with EGFR mutation, 15 (83.3{\%}) had a single mutation, and three (16.7{\%}) had double mutation. Different EGFR mutation subtypes exhibited different responses to radiotherapy. The identified double EGFR mutations were associated with reduction of residual tumor burden (RTB) after radiotherapy. In univariate analysis, EGFR mutations in exon 18, 20, and 21 and double EGFR mutation were significant factors predicting RTB. In multivariate analysis, exon 20 mutation was the only significant factor. Patients with EGFR mutation seemed to have longer mean overall survival (OS) compared to the group with wild-type EGFR (31.1 vs. 26.6 months, p=0.49). The median and mean OS in patients with double EGFR mutation vs. wild-type EGFR were 20.1 vs. 16.9 months and 28.9 vs. 26.6 months, respectively. Further studies with larger sample size are warranted to clarify the association of EGFR mutation status with the lung tumor response after radiotherapy.",
keywords = "Double EGFR mutation, Epidermal growth factor receptor mutation, Lung adenocarcinoma, Radiotherapy",
author = "Li, {Ming Hsien} and Tsai, {Jo Ting} and Ting, {Lai Lei} and Lin, {Jang Chun} and Liu, {Yu Chang}",
year = "2018",
month = "1",
day = "1",
doi = "10.21873/invivo.11226",
language = "English",
volume = "32",
pages = "203--209",
journal = "In Vivo",
issn = "0258-851X",
publisher = "International Institute of Anticancer Research",
number = "1",

}

TY - JOUR

T1 - Comparison of thoracic radiotherapy efficacy between patients with and without EGFR-mutated lung adenocarcinoma

AU - Li, Ming Hsien

AU - Tsai, Jo Ting

AU - Ting, Lai Lei

AU - Lin, Jang Chun

AU - Liu, Yu Chang

PY - 2018/1/1

Y1 - 2018/1/1

N2 - To investigate the association between tumor response to thoracic radiotherapy and epidermal growth factor receptor (EGFR) mutation status in patients with lung adenocarcinoma, we collected 48 patients treated between January 2010 and December 2013. Of the 18 patients with EGFR mutation, 15 (83.3%) had a single mutation, and three (16.7%) had double mutation. Different EGFR mutation subtypes exhibited different responses to radiotherapy. The identified double EGFR mutations were associated with reduction of residual tumor burden (RTB) after radiotherapy. In univariate analysis, EGFR mutations in exon 18, 20, and 21 and double EGFR mutation were significant factors predicting RTB. In multivariate analysis, exon 20 mutation was the only significant factor. Patients with EGFR mutation seemed to have longer mean overall survival (OS) compared to the group with wild-type EGFR (31.1 vs. 26.6 months, p=0.49). The median and mean OS in patients with double EGFR mutation vs. wild-type EGFR were 20.1 vs. 16.9 months and 28.9 vs. 26.6 months, respectively. Further studies with larger sample size are warranted to clarify the association of EGFR mutation status with the lung tumor response after radiotherapy.

AB - To investigate the association between tumor response to thoracic radiotherapy and epidermal growth factor receptor (EGFR) mutation status in patients with lung adenocarcinoma, we collected 48 patients treated between January 2010 and December 2013. Of the 18 patients with EGFR mutation, 15 (83.3%) had a single mutation, and three (16.7%) had double mutation. Different EGFR mutation subtypes exhibited different responses to radiotherapy. The identified double EGFR mutations were associated with reduction of residual tumor burden (RTB) after radiotherapy. In univariate analysis, EGFR mutations in exon 18, 20, and 21 and double EGFR mutation were significant factors predicting RTB. In multivariate analysis, exon 20 mutation was the only significant factor. Patients with EGFR mutation seemed to have longer mean overall survival (OS) compared to the group with wild-type EGFR (31.1 vs. 26.6 months, p=0.49). The median and mean OS in patients with double EGFR mutation vs. wild-type EGFR were 20.1 vs. 16.9 months and 28.9 vs. 26.6 months, respectively. Further studies with larger sample size are warranted to clarify the association of EGFR mutation status with the lung tumor response after radiotherapy.

KW - Double EGFR mutation

KW - Epidermal growth factor receptor mutation

KW - Lung adenocarcinoma

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=85039738799&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039738799&partnerID=8YFLogxK

U2 - 10.21873/invivo.11226

DO - 10.21873/invivo.11226

M3 - Article

AN - SCOPUS:85039738799

VL - 32

SP - 203

EP - 209

JO - In Vivo

JF - In Vivo

SN - 0258-851X

IS - 1

ER -